Janney Montgomery Scott LLC Acquires 46,398 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Janney Montgomery Scott LLC increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 15.3% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 349,730 shares of the company’s stock after buying an additional 46,398 shares during the period. Janney Montgomery Scott LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $11,618,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of TEVA. Country Club Trust Company n.a. increased its position in Teva Pharmaceutical Industries Limited by 5.7% in the first quarter. Country Club Trust Company n.a. now owns 164,839 shares of the company’s stock valued at $5,290,000 after buying an additional 8,870 shares during the last quarter. Berson & Corrado Investment Advisors LLC bought a new position in Teva Pharmaceutical Industries Limited during the first quarter valued at $1,072,000. Northstar Group Inc. increased its position in Teva Pharmaceutical Industries Limited by 68.4% in the first quarter. Northstar Group Inc. now owns 21,548 shares of the company’s stock valued at $694,000 after buying an additional 8,750 shares during the last quarter. Trust Co increased its position in Teva Pharmaceutical Industries Limited by 71.7% in the fourth quarter. Trust Co now owns 28,569 shares of the company’s stock valued at $1,035,000 after buying an additional 11,929 shares during the last quarter. Finally, Manning & Napier Advisors LLC increased its position in Teva Pharmaceutical Industries Limited by 15.0% in the first quarter. Manning & Napier Advisors LLC now owns 96,678 shares of the company’s stock valued at $3,101,000 after buying an additional 12,645 shares during the last quarter. 56.27% of the stock is owned by institutional investors.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 0.64% during mid-day trading on Friday, reaching $17.30. The company had a trading volume of 25,074,977 shares. The company’s market capitalization is $17.58 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $16.81 and a 52-week high of $55.39. The company’s 50-day moving average price is $30.08 and its 200-day moving average price is $31.67.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.25 EPS. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -18.95%.

TRADEMARK VIOLATION NOTICE: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/11/janney-montgomery-scott-llc-raises-stake-in-teva-pharmaceutical-industries-limited-nyseteva-updated.html.

Several equities analysts have weighed in on TEVA shares. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research report on Monday, April 17th. Deutsche Bank AG lowered their price objective on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating for the company in a research report on Friday, May 12th. Vetr raised Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $34.25 price objective for the company in a research report on Wednesday, May 17th. Citigroup Inc. lowered their price objective on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, April 25th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $38.00 price objective (down previously from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, May 15th. Three research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and a consensus price target of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit